NASDAQ · BFRIW

Biofrontera Inc.

$0.03 -$0.01 (-28.57%) 1D Market open

Key Metrics

$221.85K
Market cap
P/E · TTM
$43.20M
Revenue · TTM
−$11.09M
Net income
EPS · TTM $-1.25
Dividend yield
Free cash flow −$9.32M
Beta · 1Y 1.42
EBITDA · TTM −$10.89M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    The stock moved +77.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 21
  • Jul 17
    From its Mar 17 high, the share price fell 73%.

    Peak close $0.07 on Mar 17; trough close $0.02 on Jul 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -73%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 19
    The stock moved +60.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 19

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.02 – $0.19
Avg volume · 20D35.0K
Net cash
Book value / share$0.68
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Biofrontera Inc.
IPO dateOct 29, 2021
Employees94

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.01
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -25.6%
Net -25.7%
FCF -21.6%
ROE / ROIC -211.1% · 4,487.4%

Financial Health

Current ratio1.20
Quick ratio1.09
Debt / equity
Debt / EBITDA
Net cash
Working capital$2.24M

Cash Flow · TTM

Operating CF −$9.31M
Capex −$4.00K
Free cash flow −$9.32M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-7.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings